|
Oryzon is the first Spanish company in functional genomics. Incorporated in 2000, the company is a paradigm of high growth in the emergent Spanish Biotech sector.
The company at a glance: Venture Backed (Najeti SCR) Close to 80 employees. A young and multinational team 6,5 M € of revenues in 2008 Five consecutive years on net profits 6 Affiliated companies An IPO oriented funding strategy A Biomarker discovery company focused in oncology and neurodegeneration Extending activities from diagnostics to therapy through biologics Strong appetite for international partnerships (companies/academy) Ready to CO-Develop new targets oriented to product development Happy to in-license IP (targets in oncology / CNS / Technology) Wanting to Attract human talent  |
|